News & Media

News and features

15 December 2006

Interim Report for the six months ended 30 September 2006

1 December 2006

Interim Results for the six months ended 30 September 2006

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce...

17 November 2006

Placing of new ordinary shares

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces the placing...

25 October 2006

AGM Statement

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, will hold...

27 September 2006

Report and Financial Statements 31 March 2006

27 September 2006

Collaboration with the US National Institutes of Health

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce a collaboration with...

20 September 2006

Preliminary Results for the year ended 31 March 2006

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce its preliminary results...

24 May 2006

Collaboration with the University of California, Los Angeles

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce...

21 March 2006

Commencement of Phase II trial in prevention of migraine

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce...

8 March 2006

Appointment of Nomura Code Securities Ltd as Nominated Adviser and Broker

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce the appointment...

13 January 2006

Minster Pharmaceuticals to collaborate with Copenhagen of University

Minster Pharmaceuticals to collaborate with University of Copenhagen to investigate the potential of tonabersat in the prevention of migraine with aura...